Company intelligence / Profile preview
Evopoint Biosciences
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Evopoint has a robust pipeline with over seven clinical-stage programs and more than ten at discovery/preclinical stages. Lead asset XNW5004 is a selective EZH2 inhibitor in pivotal studies for relapsed/refractory PTCL and in combination trials with pembrolizumab for advanced solid tumors. Other assets include ADCs targeting CLDN18.2 and novel antibiotics/anti-infectives[6][8]. Interim results show promising efficacy and safety profiles.
- Therapeutic areas
- Metabolic DisordersOncologyInfectious Diseases
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)Monoclonal antibodiesTargeted protein degraders (TPD/PROTACs)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
MSD/Merck & Co.: Clinical trial collaboration for XNW5004 + KEYTRUDA® in advanced solid tumors[8][10].MediLink Therapeutics: Discovery collaboration on linker-payload system for ADCs XNW27011/XNW28012[6].Additional partnerships with global/domestic firms not individually named[2].
Beyond the preview
Go deeper on Evopoint Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evopoint Biosciences.